Join Growin Stock Community!

National research corporationNRC.US Overview

US StockHealthcare
(No presentation for NRC)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NRC AI Insights

NRC Overall Performance

NRC AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NRC Recent Performance

5.17%

National research corporation

0.05%

Avg of Sector

-0.31%

S&P500

NRC PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NRC Key Information

NRC Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NRC Profile

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.

Price of NRC

NRC FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NRC Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.51
PE Ratio (TTM)
26.82
Forward PE
-
PS Ratio (TTM)
2.21
PB Ratio
21.68
Price-to-FCF
19.93
METRIC
VALUE
vs. INDUSTRY
Gross Margin
60.32%
Net Margin
8.44%
Revenue Growth (YoY)
-3.96%
Profit Growth (YoY)
-3.78%
3-Year Revenue Growth
-2.65%
3-Year Profit Growth
-7.51%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.51
PE Ratio (TTM)
26.82
Forward PE
-
PS Ratio (TTM)
2.21
PB Ratio
21.68
Price-to-FCF
19.93
Gross Margin
60.32%
Net Margin
8.44%
Revenue Growth (YoY)
-3.96%
Profit Growth (YoY)
-3.78%
3-Year Revenue Growth
-2.65%
3-Year Profit Growth
-7.51%

  • When is NRC's latest earnings report released?

    The most recent financial report for National research corporation (NRC) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NRC's short-term business performance and financial health. For the latest updates on NRC's earnings releases, visit this page regularly.

  • Where does NRC fall in the P/E River chart?

    According to historical valuation range analysis, National research corporation (NRC)'s current price-to-earnings (P/E) ratio is 56.89, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of NRC?

    According to the latest financial report, National research corporation (NRC) reported an Operating Profit of 4.67M with an Operating Margin of 13.26% this period, representing a decline of 51.31% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is NRC's revenue growth?

    In the latest financial report, National research corporation (NRC) announced revenue of 35.19M, with a Year-Over-Year growth rate of -4.64%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does NRC have?

    As of the end of the reporting period, National research corporation (NRC) had total debt of 79.04M, with a debt ratio of 0.59. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does NRC have?

    At the end of the period, National research corporation (NRC) held Total Cash and Cash Equivalents of 4.14M, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does NRC go with three margins increasing?

    In the latest report, National research corporation (NRC) achieved the “three margins increasing” benchmark, with a gross margin of 54.31%%, operating margin of 13.26%%, and net margin of 5.11%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess NRC's profit trajectory and future growth potential.

  • Is NRC's EPS continuing to grow?

    According to the past four quarterly reports, National research corporation (NRC)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.08. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NRC?

    National research corporation (NRC)'s Free Cash Flow (FCF) for the period is 6.06M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 213.07% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of NRC?

    The latest valuation data shows National research corporation (NRC) has a Price-To-Earnings (PE) ratio of 56.89 and a Price/Earnings-To-Growth (PEG) ratio of -1.05. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.